SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes
Yuliya Lytvyn(University Health Network), David Z.I. Cherney(University Health Network), Laura Pyle(University of Colorado Anschutz Medical Campus), Petter Bjornstad(University of Colorado Denver), Alexandra Katz(University of Toronto), Ronan Roussel(Lyon 1 Université), Sunita Singh(University Health Network), Lap‐Ping Chung(University of Colorado Denver), Bruce A. Perkins(Sinai Health System), Carissa Vinovskis(University of Colorado Denver), Lucas C. Godoy(University of Toronto)
Cited by 25
Related Papers
Association of Cardiometabolic Multimorbidity With Mortality
|JAMA|2015|1.2k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life
|JAMA Cardiology|2020|248
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216